Vertex Pharmaceuticals Inc
VRTX
$510.26+2.36%
Delayed · as of Oct 15, 2026, 1:43 PM ET
Mkt cap
$106.87B
EV/Sales
8.48
P/E ratio
29.7
FY2025 Revenue
$12.00B
EPS (TTM)
$17.17
Gross Margin (FY2025)
86.24%
Profit Margin (FY2025)
32.94%
Beta
0.43
Div yield
N/A
Sector
Healthcare
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Use this VRTX research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full VRTX income, balance, and cash tables.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company in the Healthcare sector.
Latest cached Vertex Pharmaceuticals Inc (VRTX) revenue for Dec 31, 2025 was $12.00B. Net income was $3.95B. Statements: https://lician.com/financials/vrtx
Vertex Pharmaceuticals Inc (VRTX) trailing P/E is 29.7 on the latest cached fundamentals snapshot.
Vertex Pharmaceuticals Inc (VRTX) market capitalization is $106.87B on the latest cached snapshot.
Vertex Pharmaceuticals Inc (VRTX) cached previous close $498.50; day range $510.26 – $514.91; volume 771,900. Session quote: https://lician.com/quote/vrtx
Vertex Pharmaceuticals Inc (VRTX) latest cached earnings event is "VRTX earnings" on Aug 3, 2026. Earnings calendar: https://lician.com/earnings
The latest cached VRTX filing is 8-K · Sep 1, 2026. Filings: https://lician.com/sec/vrtx